Retrophin (RTRX) Names Margaret Valeur-Jensen, Ph.D. As General Counsel

NEW YORK--(BUSINESS WIRE)--Retrophin, Inc. (NASDAQ:RTRX) today announced the appointment of Margaret Valeur-Jensen, Ph.D. to the newly created position of General Counsel, effective immediately. She will be responsible for providing legal advice regarding the Company's commercial operations, research activities, business development and compliance with industry standards.

Suggested Articles

Smaller biotechs are continuing their biopharma hiring spree as two startups nab some big names for their aspiring cancer drug research.

In a 7-2 vote, an FDA panel backed Aimmune’s peanut allergy treatment for approval. It desensitizes patients with increasing doses of peanut protein.

In a phase 1 trial of Atara's T-cell therapy for MS, patients who received the highest of the two doses reported showed an improvement in symptoms.